Company news
Aptorum Group Limited (NASDAQ:APM) news
Aptorum Group Limited news releases on 6ix. Latest, Jan 10, 2022: Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small…
Press releases — page 2
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
January 9, 2022
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
December 2, 2021
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
October 18, 2021
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021
September 14, 2021
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
September 14, 2021
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
July 11, 2021
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
May 23, 2021
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
May 5, 2021
Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases
April 21, 2021
Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
March 30, 2021
Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
January 19, 2021
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
December 20, 2020
Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders
December 9, 2020
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020
October 15, 2020
Aptorum Group Announces Closing of $9.0 Million Public Offering
October 1, 2020
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome
September 28, 2020
Aptorum Group Announces Pricing of $9.0 Million Public Offering
September 28, 2020
Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance
September 7, 2020
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020
August 31, 2020
Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types
August 31, 2020
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models
August 31, 2020
Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others
August 19, 2020
Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
March 29, 2020
Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform
March 29, 2020
Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants
February 27, 2020
Aptorum Group Announces Pricing of $10 Million Registered Direct Offering
February 25, 2020
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
February 23, 2020
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
February 9, 2020
Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020
February 9, 2020
Aptorum Group Limited Announces Results of 2019 Annual General Meeting
November 14, 2019
Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA
September 9, 2019
Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
September 8, 2019